Amyloidosis Masterclass

January 10, 2020
8 am – 3:30 pm

Dallas, Texas

AMYLOIDOSIS MASTERCLASS

The Art and Science of Managing Amyloidosis

REGISTER

The diagnostic, treatment and clinical trial landscape is fast evolving in systemic amyloidosis. With the approval of new treatments for ATTR amyloidosis, it has never been more important to ensure that the complexities associated with treating these multi-systemic, progressive diseases are well understood, and patients are quickly and correctly diagnosed and have access to appropriate treatment.

ARC has partnered with Boston University School of Medicine (BUSM) to provide a 1-day live AMA PRA-accredited conference. This Masterclass is led by an Internationally renowned faculty of amyloidosis experts. It is open to healthcare practitioners of all disciplines.

REGISTER

What You’ll Learn

Masterclass attendees will learn:

  • Skills to address the challenges in identifying, correctly typing and treating amyloidosis patients in their clinical practices.
  • Detailed information about amyloidosis care, and  up-to-date information on diagnostic tools, current treatment options and the clinical trial landscape.
  • Best practices in building a multidisciplinary amyloidosis program to best support patients.

REGISTER

LOCATION

The Westin Dallas Fort Worth Airport
4545 West John Carpenter Freeway
Irving, Texas

AGENDA

January 10, 2020
8 am-3:30 pm


SESSION 1: DIAGNOSING AMYLOIDOSIS

8:30 – Introduction (15 mins)
Vaishali Sanchorawala, MD

  • Purpose of Masterclass
  • Current State of the Field
  • Impacts of Delayed Diagnosis


8:45 – When to suspect amyloidosis
(15 mins)
Lisa Mendelson, NP

  • Symptoms and Suspicion
  • Red Flags


9:00 – How to diagnose amyloidosis
(15 mins)
Anita D’Souza, MD

  • Diagnostic Tools
  • Diagnostic Algorithm

SESSION 2 : MANAGEMENT OF AL AMYLOIDOSIS

9:15 – Staging and Risk stratification in AL amyloidosis (10 mins)
Vaishali Sanchorawala, MD

9:30 – Current therapies in AL amyloidosis (30 mins)
Larry Anderson, MD

  • Standard of care
  • Novel agents
  • Role of stem cell transplantation


10:00 – Quality of life in AL amyloidosis
(10 mins)
Anita D’Souza, MD 

10:15 – How to approach patients with advanced AL amyloidosis (15 mins)
Anita D’Souza, MD

10:30 – Discussion: Challenges of AL therapies and clinical trials (20 mins)
All Faculty

10:50-11:05 – Break 


SESSION 3 –MANAGEMENT OF ATTR AMYLOIDOSIS

11:05 – Introduction (10 mins)
John Berk, MD

  • Epidemiology of hATTR and ATTRwt
  • Importance of early diagnosis and symptom monitoring in hATTR (How early should you target treatment?)
  • Staging and Risk stratification


11:15 – Cardiac ATTR amyloidosis
(20 mins)
Mat Maurer, MD

Advances in TTR protein stabilization and degradation of amyloid fibrils for ATTR amyloidosis

11:35 – Neuro ATTR amyloidosis (20 mins)
Sami Khella, MD

  • Neuropathy burden and management
  • Impact of gene silencers
  • Neuropathy scales for clinical practice and trials


11:55 – Use of PYP Scintigraphy
(10 mins)
Mat Maurer, MD

12:05 – Genetic Testing and Counseling (10 mins)
John Berk

12:15 – Discussion: Sequencing of TTR stabilizers and silencers in the treatment of ATTR, new clinical trials (20 mins)
All

12:35-1:30 – Lunch 


1:30

SESSION 4: BREAK OUT SESSIONS WITH HANDS ON TEACHING

(20 minutes rotation)

Track 1: Fat Pad Aspiration
Lisa Mendelson, NP

Track 2: Reading PYP Scintigraphy
Mat Maurer, MD

Track 3: Specialty Pharmacy and Prior Authorizations
David Hughes, PharmD


SESSION 5: MULTIDISCIPLINARY APPROACH TO AMYLOIDOSIS

2:30-2:50
Vaishali Sanchorawala, MD

  • Why multidisciplinary is important
  • BU model of care


3:00

Discussion: Collaboration with referral centers
All faculty

3:30
End

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Amyloidosis Research Consortium. . Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the masterclass.

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization